Amberstone Biosciences’ transformative immunotherapeutics eliminate the issues of dose toxicity interfering with drug efficacy by introducing a safer class of therapeutic agents. Traditional therapies can be extremely effective at destroying tumors. However, the high dosage required for efficacy often has devastating effects. Our technology (T-MATE™) allows us to target only the tumor without damaging healthy tissues.
Pipeline therapeutic discoveries start with our AmberFlow™ platform technology. Driven by proprietary single-cell microfluidics, AmberFlow™ adds the element of a directly assayable and tunable microenvironment so valuable qualitative data can be obtained much further upstream in the discovery process.